Dr. Weiping Wang is currently an Associate Professor at the Department of Pharmacology and Pharmacy & Dr. Li Dak-Sum Research Centre, The University of Hong Kong. He is also a Principal Investigator at the State Key Laboratory of Pharmaceutical Biotechnology at HKU. He obtained his Ph.D. (supervisor: Prof. Ying Chau) in Chemical Engineering from The Hong Kong University of Science and Technology in 2011. He worked as a Research Fellow (supervisor: Prof. Daniel Kohane) at Boston Children's Hospital, Harvard Medical School and Postdoctoral Associate (supervisor: Prof. Robert Langer) at Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology.

Dr. W.P. Wang and his research associates

Memberships

• Member of American Institute of Chemical Engineers
• Member of Society for Biological Engineering
• Lifetime Member of Chinese Association for Biomaterials
• Member of Controlled Release Society

Editorships

Guest Editor, Special Issue on Advanced Technologies for Biomedical Applications by Emerging Researchers in Asia-Pacific, Bioengineering & Translational Medicine, Wiley Publishing, 2022-2023

Guest Editor, Special Topic on Drug/Gene Delivery and Theranostics, APL Bioengineering, American Institute of Physics (AIP) Publishing, 2022-2023

Honours and Awards

• NSFC Excellent Young Scientists Fund (Hong Kong and Macau), National Natural Science Foundation of China (NSFC), 2022
• Gold Medal, Special Edition 2022 Inventions Geneva Evaluation Days, 2022
• Thieme Chemistry Journals Award, Thieme Chemistry Journals, 2021
• Journal of Materials Chemistry B Emerging Investigator, Royal Society of Chemistry, 2020
• Faculty Outstanding Research Output Award, Li Ka Shing Faculty of Medicine, HKU, 2020
• Young Innovator Award in Nanobiotechnology (NR 45, 45 outstanding young investigators under 45), Nano Research, Tsinghua University Press & Springer Nature, 2018

• Photoresponsive drug delivery systems (No. 82222903), 2023-2025, PI, NSFC Excellent Young Scientists Fund, RMB 2,000,000
• Development of photoresponisve prodrug nanoparticles based on mTOR inhibitors for the treatment of skin cancer (No. 09201616), 2022-2025, PI, Health and Medical Research Fund, HKD 1,419,200
• Development of near-infrared light-triggered drug delivery system, 2021-2022, PI, Karolinska Institutet’s MWLC Associate Member Programme, HKD 525,000
• Low-irradiance red light-triggered drug release for the treatment of retinoblastoma (No. 27115220), PI, Early Career Scheme of Research Grants Council, 2020-2023, HKD 936,520
• Development of Photo-targeted Nanocarriers for Esophageal Cancer Therapy (No. 07181936), PI, Health and Medical Research Fund, 2020-2023, HKD 1,405,630
• Engineering nanomaterials for drug delivery, genome editing and bioimaging, PI, Karolinska Institutet’s MWLC Associate Member Programme, 2019-2020, HKD 525,000
• Development of ultrasound-responsive polymeric nanoreactors for retinoblastoma therapy (No. 06173456), PI, Health and Medical Research Fund, 2019-2021, HKD 1,499,628
• Hydrogen sulfide-responsive small-molecule nanoparticles as drug delivery carriers (No. 81803469), PI, Young Scientists Fund of the National Natural Science Foundation of China, 2019-2021, RMB 210,000
• Preparation of Self-assembled Nanodrugs (SANDs) by an Ice-template Assisted Method (No. ITS/372/17), Co-PI, Hong Kong Innovation and Technology Support Programme, 2018-2019, HKD 300,000 allocated
• Photoresponsive nanoparticles inducing cellular autophagy and enhancing targeted drug delivery for cancer therapy (No. 2017A050506016), Co-PI, Guangdong-Hong Kong Technology Cooperation Funding Scheme, 2017-2019, RMB 150,000 allocated

• Weiping Wang, Kaiqi Long, Yifan Wang, Photocleavable prodrug-based nanomedicine for in-situ monitorable cancer therapy, PCT Patent (No. PCT/CN2022/124524, 2022)
• Weiping Wang, Yuwei Liu, Kaiqi Long, Photoresponsive prodrugs for targeted immunotherapy, US Provisional Patent (No. 63/203,687, 2021)
• Weiping Wang, Kaiqi Long, Shuting Xu, Photoactivatable prodrug nanoparticles for combined anti-angiogenesis and photodynamic therapy, PCT Patent (No. PCT/CN2022/107621, 2022)
• Weiping Wang, Yaming Zhang, ROS-responsive prodrugs and compositions and methods of thereof, PCT Patent (No. PCT/CN2022/104160, 2022)
• Weiping Wang, Tianyi Wang, Kaiqi Long, Compositions and Methods of optochemical control of mTOR signaling and mTOR-dependent autophagy, CN Patent (No. 202210749138.6, 2022), US Patent (No. 17/850,720, 2022)
• Weiping Wang, Yang Zhou, Yafei Li, A photoresponsive delivery system based on a modified PAMAM and methods thereof, PCT Patent (No. PCT/CN2022/097804, 2022)
• Weiping Wang, Yafei Li, Compositions and methods of macropinocytosis inhibitors to treat cancers, PCT Patent (No. PCT/CN2022/092398, 2022)
• Weiping Wang, Kaiqi Long, A controlled drug release system of photoresponsive nanocarriers, methods of making and using thereof, PCT Patent (No. PCT/CN2021/081262, 2021), CN Patent (Application No. 202180029535.X, 2022), US Patent (Application No. 17/904,833, 2022), European Patent (Application No. 21793651.7, 2022)
• Weiping Wang, Wen Lyv, Triplet-triplet energy transfer with light excitation at long wavelengths and methods thereof, PCT Patent (No. PCT/CN2019/101689, 2019), CN Patent (No. 201980054786.6, 2021), US Patent (No. 17/262,452, 2021).